These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 34370645)

  • 1. Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review.
    Gitto M; Vrachatis DA; Condorelli G; Papathanasiou K; Reimers B; Deftereos S; Stefanini GG
    Cardiovasc Hematol Agents Med Chem; 2022; 20(2):90-102. PubMed ID: 34370645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.
    Brown E; Wilding JPH; Alam U; Barber TM; Karalliedde J; Cuthbertson DJ
    Ann Med; 2021 Dec; 53(1):2072-2089. PubMed ID: 33107349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure.
    Greene SJ; Butler J; Kosiborod MN
    Am J Med; 2024 Feb; 137(2S):S25-S34. PubMed ID: 38184323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review of the Economic Evaluation of Sodium-Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure.
    Nam K; Cho DS; Kim H; Kwon B; Yoon Y; Park C; Kim ES; Youn JC; Park SK
    Clin Drug Investig; 2023 Jul; 43(7):463-474. PubMed ID: 37365452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure.
    Chen K; Nie Z; Shi R; Yu D; Wang Q; Shao F; Wu G; Wu Z; Chen T; Li C
    JAMA Netw Open; 2023 Aug; 6(8):e2330754. PubMed ID: 37615988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardioprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors and Their Possible Association With Normalization of the Circadian Index of Heart Rhythm.
    Dogan NB; Yasar HY; Kilicaslan B
    Tex Heart Inst J; 2023 Dec; 50(6):. PubMed ID: 38083821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Expanding Horizons Beyond Diabetes Management.
    Fatima A; Rasool S; Devi S; Talha M; Waqar F; Nasir M; Khan MR; Ibne Ali Jaffari SM; Haider A; Shah SU; Sapna F; Varrassi G; Khatri M; Kumar S; Mohamad T
    Cureus; 2023 Sep; 15(9):e46243. PubMed ID: 37908957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose cotransporter-2 inhibitors in heart failure patients across the range of body mass index: a systematic review and meta-analysis of randomized controlled trials.
    Adamou A; Chlorogiannis DD; Kyriakoulis IG; Stamatiou I; Koukousaki D; Kardoutsos I; Sagris D; Doehner W; Ntaios G
    Intern Emerg Med; 2024 Mar; 19(2):565-573. PubMed ID: 38353880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization rates and predictors of sodium glucose cotransporter 2 inhibitor use in patients with heart failure with or without type 2 diabetes.
    Bermudez SR; Anderson JR; Bos AJ; Ray GM
    Am J Health Syst Pharm; 2023 Dec; 80(24):1787-1795. PubMed ID: 37551996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients.
    Kashiwagi A; Araki S; Maegawa H
    J Diabetes Investig; 2021 Jan; 12(1):6-20. PubMed ID: 32563214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: new guidelines hot off the press and directly into guidelines!
    Clark KAA
    Postgrad Med J; 2023 Sep; 99(1176):1052-1057. PubMed ID: 37001168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis.
    Cardoso R; Graffunder FP; Ternes CMP; Fernandes A; Rocha AV; Fernandes G; Bhatt DL
    EClinicalMedicine; 2021 Jun; 36():100933. PubMed ID: 34308311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of sodium-glucose cotransporter 2 inhibitors in heart failure.
    Gitto M; Villaschi A; Federici M; Condorelli G; Stefanini GG
    Curr Pharm Des; 2023 Feb; ():. PubMed ID: 36799420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similarities and distinctions between acetazolamide and sodium-glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE.
    Packer M; Butler J
    Eur J Heart Fail; 2023 Sep; 25(9):1537-1543. PubMed ID: 37403655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs.
    Hussain A; Ramsey D; Lee M; Mahtta D; Khan MS; Nambi V; Ballantyne CM; Petersen LA; Walker AD; Kayani WT; Butler J; Slipczuk L; Rogers JG; Bozkurt B; Navaneethan SD; Virani SS
    JACC Heart Fail; 2023 Aug; 11(8 Pt 1):933-942. PubMed ID: 37204363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibitors' Cardiovascular Benefits in Individuals Without Diabetes, Heart Failure, and/or Chronic Kidney Disease: A Systematic Review.
    Khiali S; Taban-Sadeghi M; Sarbakhsh P; Khezerlouy-Aghdam N; Rezagholizadeh A; Asham H; Entezari-Maleki T
    J Clin Pharmacol; 2023 Dec; 63(12):1307-1323. PubMed ID: 37455561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DAPA-HF applicability: the point of view of a cardiology setting.
    Iacoviello M; Marini M; Gori M; Orso F; Gonzini L; Gorini M; Fenici P; Maggioni AP
    Acta Cardiol; 2023 Sep; 78(7):840-845. PubMed ID: 37605991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanded use of sodium-glucose cotransporter 2 inhibitors: Evidence beyond heart failure with reduced ejection fraction.
    Schoenborn EM; Skersick PT; Thrasher CM; Page RL
    Pharmacotherapy; 2023 Sep; 43(9):950-962. PubMed ID: 37323057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease.
    Khater J; Malakouti S; Khoury AE; Cortese B
    J Cardiovasc Med (Hagerstown); 2024 Apr; 25(4):247-258. PubMed ID: 38305141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure-Current Evidence in Special Populations.
    Moady G; Ben Gal T; Atar S
    Life (Basel); 2023 May; 13(6):. PubMed ID: 37374037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.